| Carle Richland Memorial Hospital | |
| 800 East Locust, Olney, Illinois 62450 | |
| (618) 395-2131 | |
| Name | Carle Richland Memorial Hospital |
|---|---|
| Type | Acute Care Hospital |
| Location | 800 East Locust, Olney, Illinois |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | Yes |
| Medicare ID (CCN) | 140147 |
| NPI Number | 1003131327 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 618-395-2131 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| NPI Number | 1306973607 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 618-395-7340 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| NPI Number | 1467492124 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL, INC |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 618-395-7340 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| NPI Number | 1497882799 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 618-395-7340 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| NPI Number | 1508932096 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL, INC |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 618-395-7340 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| NPI Number | 1528014834 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL, INC |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | Psychiatric Hospital |
| Phone Number | 618-395-7340 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| NPI Number | 1770610073 |
| Organization Name | RICHLAND MEMORIAL HOSPITAL |
| Address | 800 E Locust St, Olney, IL 62450 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 618-395-7340 |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
| Able to receive lab results electronically | Yes |
| Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means.
Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
"For the poor, cancer remains a silent killer. Breaking this silence could save hundreds of thousands and likely even millions of lives each year - most of them in developing, low- and middle-income countries (LMICs)," Felicia Knaul, secretariat co-director of the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, writes in the Huffington Post's "World" blog.
› Verified 3 days ago
Carle Richland Memorial Hospital Acute Care Hospital Location: 800 East Locust, Olney, Illinois 62450 Phone: (618) 395-2131 |